Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Leukemia 1

Interventions

Imatinib Mesylate 6Cytarabine 5ponatinib 4nilotinib 4venetoclax 3fludarabine phosphate 3Mycophenolic Acid 3thymoglobulin 2fludarabine 2enasidenib 2Methotrexate 2Lenalidomide 2Cyclosporine 2Cyclophosphamide 2Azacitidine 2Antilymphocyte Serum 2quizartinib 1methanesulfonic acid 1glasdegib 1etoposide phosphate 1daratumumab 1bosutinib 1asciminib 1Whole-Body Irradiation 1Transplantation 1Temozolomide 1Tacrolimus 1Stem Cell Transplantation 1Standard of Care 1RFT5-SMPT-dgA immunotoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Myeloid × IMC-EB10 × Clear all
NCT00887926 2022-12-22

Study of IMC-EB10 in Participant With Leukemia

Eli Lilly and Company

Phase 1 Terminated
25 enrolled 13 charts
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡